1. McGeer PL and McGeer EG. Local neuroinflammation and progression of Alzheimer's disease. J Neurovirology 202; 8: 529-538.
2. Tavares RG, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002; 40: 621-627.
3. Eastman CL, et al. Increased brain quinolinic acid production in mice infected with a neurotropic measles virus. Exp Neurol 1994; 125; 119-124.
4. Glass JD and Wesselingh SL. Microglia in HIV-associated neurological diseases. Microsc Res Tech 2001; 54: 95-105.
5. Turowski RC and Troozzi PL. Central Nervous System toxicities of cytokine therapy: In: Plotnikoff NP, et al, Eds. Cytokines, Stress and Immunity. Boca Raton, CRC Pres, 1998, pp 93-114.
6. Mrak RE, et al. Glail cytokines and Alzheimer's disease: Review and pathogenic implications. Human Pathol 1995; 26: 816-823.
7. Klatschmidt C, et al. Stimulation of inotropic glutamate receptors activates transcription factor NFkB in primary neurons. Proc Nat Acad Sci USA 1995; 92: 9618-9622.
8. Gao HM, et al Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002; 22: 782-790.
9. Dyatlov VA et al. neonatal lead exposure potentates sickness behavior by Listeria monocytogenes infection in mice. Brain Behav Immun 2002; 16: 477-492.
10. Nakai Y, et al. Apoptosis and microglial activation in influenza encephalopathy. Acta Neuropath (Berl) 2003; 105: 233-239.
11. Anderson T et al. NMDA-receptor antagonist prevents measles virus-induced neurodegeneration. Eur J Neurosci 1991; 3: 66-71.
12. Conner TJ, et al. Depression stress immunological activation: the role of cytokines in depressive disorders. Life Sciences 1998; 62: 583-606.
13. Renault PF, et al. Psychiatric complications of long-term ineterferon-alpha therapy. Arch Internal Medicine 1987; 147: 1577-1580.
14. Adams F et al. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252: 938-941.
15. Broderick PA, et al. Interleukin-1a alters hippocampal and norepinephrine release during open field behavior in Sprague-Dawley animals: differences from the Fawn-Hooded animal model of depression. Prog Neuropsychopharmacol Biology 2002; 26: 1355-1372.
16. Katayama Y, et al. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues. J General Virology 1995; 76: 3201-3204.
17. Nicolson GL et al. High frequency of systemic mycoplasma infections in Gulf War Veterans and civilians with amyotrophic lateral sclerosis. J Clin Sci 2002; 9: 525-529.
18. Blaylock RL. Interaction of cytokines, excitotoxins, and reactive nitrogen and oxygen species in autism spectrum disorders. JANA 2003; 6: 21-35.
19. Blaylock RL. Central role of excitotoxicity in autism. JANA 2003; 6: 7-19. 20. Blaylock RL. Food additive excitotoxins and degenerative brain disorders. Medical Sentinel 1999; 4: 212-215.
21. Blaylock RL. Chronic microglial activation and excitotoxicity secondary to excessive immune stimulation: Possible factors in Gulf War Syndrome and Autism. J Amer Phys Surg 2004; 9: 46-51.
22. Pilc A, et al. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2007; (Epub ahead of print)
23. Palucha A, Pilc A. The involvement of glutamate in the pathophysiology of depression. 2005; 18: 262-268.
24. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003; 1003: 250-272.
25. Pittenger C, et al. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disorders Drug Targets 2007; 6: 101-115.
26. Magaki S et al. Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 2007; 42: 233-240.
27. Gao H-M et al. Synergistic dopaminergic neurotoxicity if the pesticide rotenone and inflammogen lipopolysacchride: relevance to the etiology of Parkinson's disease. J Neurosciences 2003; 23: 1228-1236.
28. Holmes C et al. Systemic infection, interleukin 1?, and cognitive decline. J Neurol Neurosurgery Psychiatry 2003; 74: 788-789.
29. Godbout JP et al. Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. The FASEB J 2005; 19: 1329-1331.
30. Perry VH et al. The impact of infection on the progression of neurodegenerative disease. Nature Rev Neuroscience 2003;4: 103-112.
31. Feiring B et al. Persisting responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunology 2006; 13: 790-796.
32. Vaccine Excepients and Media Summery Center for Disease Control and Prevention. (also the source for recommended vaccines for adults and children).
33. McGeer PL and McGeer EG. Local neuroinflammation and progression of Alzheimer's disease. J Neurovirology 202; 8: 529-538.
34. Tavares RG, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002; 40: 621-627.
35. Eastman CL, et al. Increased brain quinolinic acid production in mice infected with a neurotropic measles virus. Exp Neurol 1994; 125; 119-124.
36. Glass JD and Wesselingh SL. Microglia in HIV-associated neurological diseases. Microsc Res Tech 2001; 54: 95-105.
37. Turowski RC and Troozzi PL. Central Nervous System toxicities of cytokine therapy: In: Plotnikoff NP, et al, Eds. Cytokines, Stress and Immunity. Boca Raton, CRC Pres, 1998, pp 93-114.
38. Mrak RE, et al. Glail cytokines and Alzheimer's disease: Review and pathogenic implications. Human Pathol 1995; 26: 816-823.
39. Klatschmidt C, et al. Stimulation of inotropic glutamate receptors activates transcription factor NFkB in primary neurons. Proc Nat Acad Sci USA 1995; 92: 9618-9622.
40. Gao HM, et al Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002; 22: 782-790.
41. Dyatlov VA et al. neonatal lead exposure potentates sickness behavior by Listeria monocytogenes infection in mice. Brain Behav Immun 2002; 16: 477-492.
42. Nakai Y, et al. Apoptosis and microglial activation in influenza encephalopathy. Acta Neuropath (Berl) 2003; 105: 233-239.
43. Anderson T et al. NMDA-receptor antagonist prevents measles virus-induced neurodegeneration. Eur J Neurosci 1991; 3: 66-71.
44. Conner TJ, et al. Depression stress immunological activation: the role of cytokines in depressive disorders. Life Sciences 1998; 62: 583-606.
45. Renault PF, et al. Psychiatric complications of long-term ineterferon-alpha therapy. Arch Internal Medicine 1987; 147: 1577-1580.
46. Adams F et al. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252: 938-941.
47. Broderick PA, et al. Interleukin-1a alters hippocampal and norepinephrine release during open field behavior in Sprague-Dawley animals: differences from the Fawn-Hooded animal model of depression. Prog Neuropsychopharmacol Biology 2002; 26: 1355-1372.
48. Katayama Y, et al. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues. J General Virology 1995; 76: 3201-3204.
49. Nicolson GL et al. High frequency of systemic mycoplasma infections in Gulf War Veterans and civilians with amyotrophic lateral sclerosis. J Clin Sci 2002; 9: 525-529.
50. Blaylock RL. Interaction of cytokines, excitotoxins, and reactive nitrogen and oxygen species in autism spectrum disorders. JANA 2003; 6: 21-35.
51. Blaylock RL. Central role of excitotoxicity in autism. JANA 2003; 6: 7-19.
52. Blaylock RL. Food additive excitotoxins and degenerative brain disorders. Medical Sentinel 1999; 4: 212-215.
53. Blaylock RL. Chronic microglial activation and excitotoxicity secondary to excessive immune stimulation: Possible factors in Gulf War Syndrome and Autism. J Amer Phys Surg 2004; 9: 46-51.
54. Pilc A, et al. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2007; (Epub ahead of print)
55. Palucha A, Pilc A. The involvement of glutamate in the pathophysiology of depression. 2005; 18: 262-268.
56. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003; 1003: 250-272.
57. Pittenger C, et al. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disorders Drug Targets 2007; 6: 101-115.
58. Magaki S et al. Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 2007; 42: 233-240.
59. Gao H-M et al. Synergistic dopaminergic neurotoxicity if the pesticide rotenone and inflammogen lipopolysacchride: relevance to the etiology of Parkinson's disease. J Neurosciences 2003; 23: 1228-1236.
60. Holmes C et al. Systemic infection, interleukin 1?, and cognitive decline. J Neurol Neurosurgery Psychiatry 2003; 74: 788-789.
61. Godbout JP et al. Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. The FASEB J 2005; 19: 1329-1331.
62. Perry VH et al. The impact of infection on the progression of neurodegenerative disease. Nature Rev Neuroscience 2003;4: 103-112.
63. Feiring B et al. Persisting responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunology 2006; 13: 790-796.
64. Vaccine Excepients and Media Summery Center for Disease Control and Prevention. (also the source for recommended vaccines for adults and children).